Neuphoria Therapeutics Inc. (NEUP)

Market Cap	23.14M
Revenue (ttm)	15.66M
Net Income (ttm)	5.83M
Shares Out	1.88M
EPS (ttm)	0.00
PE Ratio	3.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,367
Open	12.96
Previous Close	12.45
Day's Range	12.13 - 13.28
52-Week Range	2.90 - 126.00
Beta	n/a
Analysts	Strong Buy
Price Target	28.00 (+127.46%)
Earnings Date	Nov 15, 2025

About NEUP

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: NEUP
• Website: https://www.neuphoriatx.com

Analyst Forecast

According to 2 analysts, the average rating for NEUP stock is "Strong Buy." The 12-month stock price target is $28.0, which is an increase of 127.46% from the latest price.

Price Target

$28.0

(127.46% upside)

Analyst Consensus: Strong Buy